To Identify An Enzyme Or Isoenzyme Patents (Class 435/7.4)
  • Publication number: 20140100128
    Abstract: The invention provides methods for the diagnosis and prognosis of cardiovascular disease, and for monitoring of the treatment of cardiovascular disease, including heart failure and cardiomyopathy. The invention further provides methods for identifying an agent for treating cardiomyopathy or heart failure, for identifying a cardiotoxic agent, and for identifying a rescue agent to reduce or prevent drug-induced toxicity, by using one or more biomarkers selelcted from the group consisting of CCDC47, HMOX1, PTX3, PAI1, IL27, IGFBP7, Emmprin, CFL2, EDIL3, NUCB1, PE D18:0-20:3/D18:1-20:2/D16:0-22:3; PE D18:0-22:5/D18:1-22:4; PE D16:1-22:6; PE P18:1-18:1/P18:0-18:2/P16:0-20:2; LPC 20:3; and PC-LI-183-D18:22-22:6, or any of the other biomarkers provided herein. The invention further provides kits for practicing the methods of the invention.
    Type: Application
    Filed: September 12, 2013
    Publication date: April 10, 2014
    Applicant: BERG LLC
    Inventors: Niven Rajin Narain, Rangaprasad Sarangarajan, Vivek K. Vishnudas, Michael Andrew Kiebish
  • Publication number: 20140099650
    Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of a phosphinothricin-N-acetyl-transferase enzyme. The claimed antibodies and methods are particularly useful for identifying and quantitating the presence of phosphinothricin-N-acetyl-transferase expressed in trangenic plants.
    Type: Application
    Filed: October 9, 2013
    Publication date: April 10, 2014
    Applicant: DOW AGROSCIENCES LLC
    Inventors: Guomin Shan, Eric H. Ma
  • Publication number: 20140093506
    Abstract: The present application relates to methods for reducing growth of a fungus having a coordination complex formed at the C-terminus of its dicer (dicer 1, ribonuclease type III) between an anion and the amino acids corresponding to the amino acids C1275, H1312, C1350 and C1352 of Dcr1 of S. pombe (fission yeast) comprising the step of contacting a fungal cell with an effective amount of an agent, wherein said agent disrupts the coordination complex formed at the C-terminus of fungal dicer between an anion and the amino acids corresponding to the amino acids C1275, H1312, C1350 and C1352 of Dcr1 of S. pombe.
    Type: Application
    Filed: November 14, 2011
    Publication date: April 3, 2014
    Inventors: Marc Buehler, Stephan Emmerth, Frederic Hai-Trieu Allain, Pierre Barraud
  • Publication number: 20140094387
    Abstract: Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer.
    Type: Application
    Filed: May 31, 2012
    Publication date: April 3, 2014
    Applicant: ONCOTHERAPY SCIENCE, INC.
    Inventors: Ryuji Hamamoto, Yusuke Nakamura, Takuya Tsunoda
  • Publication number: 20140093865
    Abstract: Methods of determining whether an analyte is present in a sample using a competitive assay are provided. Aspects of the methods include employing a competitor that provides for the obtainment of signal which is directly proportional to the amount of analyte in the sample. Also provided are devices and kits that find use in practicing the methods described herein.
    Type: Application
    Filed: September 10, 2013
    Publication date: April 3, 2014
    Inventors: Eric Espinosa, Andrew Farmer
  • Publication number: 20140093888
    Abstract: The present disclosure generally relates to highly pure plasmid compositions having low, or undetectable, levels of colanic acid and other contaminants made by a process that includes the steps of obtaining a crude lysate of a plasmid DNA from a bacteria that makes colanic acid; treating the partially purified or purified plasmid DNA with a polypeptide that digests colanic acid under conditions that digest the colanic acid; and purifying the plasmid DNA from the digested colanic acid and the colanic acid degrading enzyme by one or more chromatography steps.
    Type: Application
    Filed: December 6, 2013
    Publication date: April 3, 2014
    Applicant: GRADALIS, INC.
    Inventor: Nancy Smyth Templeton
  • Patent number: 8685666
    Abstract: This invention provides antibodies immunologically specific for human ARL-1 (also referred to AKR1B10), a species of the aldo-keto reductase superfamily of proteins. The invention also provides methods of making and methods of using said antibodies.
    Type: Grant
    Filed: January 31, 2011
    Date of Patent: April 1, 2014
    Assignee: The Board of Trustees of Southern Illinois University
    Inventor: Deliang Cao
  • Patent number: 8685658
    Abstract: Compositions and methods are provided for identifying agents which have efficacy for the treatment of disorders related to aberrant cilial structure and function, including polycystic kidney disease.
    Type: Grant
    Filed: July 17, 2007
    Date of Patent: April 1, 2014
    Assignee: Fox Chase Cancer Center
    Inventors: Erica A. Golemis, Elena N. Pugacheva
  • Publication number: 20140086838
    Abstract: The identification is disclosed of a new molecular factor for the early diagnosis of urothelial carcinoma of the bladder. HtrA1 is a molecule that is produced mainly by the urothelium of the bladder, both in physiological and inflammatory pathologies, such as cystitis, whereas it is absent in the urothelial layer of the neoplastic bladder mucosa, regardless of cancer grade and level. By means of Western Blotting two forms of HtrA1 were identified, both in bladder tissue and urine, the native 50 kDa form and the autocatalytic 38 kDa form. The 38 kDa form is significantly underexpressed in tumoral tissues compared with normal tissues and concentration of the 50 kDa form in urine is significantly higher in patients affected by bladder cancer compared to healthy subjects and subjects with cystitis. Therefore, the evaluation of tissutal and urinary HtrA1 levels can be a specific marker of urothelial carcinoma of the bladder.
    Type: Application
    Filed: May 2, 2012
    Publication date: March 27, 2014
    Inventors: Teresa LORENZI, Emanuele ZANNINI,, Stefano LORENZI, Mario CASTELLUCCI, Manrico MORRONI, Maria LORENZI
  • Publication number: 20140087965
    Abstract: The present invention relates to a marker which can be used to diagnose a diabetic retinopathy patient and determine the progression of diabetic retinopathy, a composition for diagnosing diabetic retinopathy, which comprises an agent for measuring the level of a gene or protein associated with the marker, and the use thereof.
    Type: Application
    Filed: September 25, 2013
    Publication date: March 27, 2014
    Applicants: SNU R&DB FOUNDATION, LG ELECTRONICS INC.
    Inventors: Yunhee KU, Youngsoo KIM, Seungyeon SONG, Jonghwa JIN, Moosub KIM, Yongju YANG
  • Publication number: 20140086899
    Abstract: The present disclosure relates generally to the field of diagnostic and prognostic assays for a condition or event of a vascular system such as the cerebrovascular system. An assay is taught herein for monitoring progression of a condition or event of a vascular system such as the cerebrovascular system as well as determining the state or stage of the condition or event. The assay of the present disclosure is also useful in the stratification of a subject based on the stage or development of the condition or event.
    Type: Application
    Filed: January 27, 2012
    Publication date: March 27, 2014
    Applicant: COMMONWEALTH SCIENTIFIC AND INDUSTRIAL RESEARCH ORGANISATION
    Inventors: David William Howells, William John Wilson
  • Publication number: 20140087365
    Abstract: An object of the present invention is to provide an immunochromatographic detection method comprising a step of detecting the failure to add a specimen and an immunochromatographic test strip comprising a means for detecting the failure to add a specimen. The inventers provides an immunochromatographic detection method and an immunochromatographic test strip capable of detecting the failure to add a specimen through a step and a means using an antibody solid-phased on an insoluble membrane for capturing the complex of a component (control component) contained in the specimen other than the analyte and a label to which an antibody to the component is immobilized so as to detect the presence or absence of the control component, in an immunochromatographic detection method of detecting an analyte in a sample acquired by diluting the specimen.
    Type: Application
    Filed: March 29, 2012
    Publication date: March 27, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Motoki Morita, Koji Kobayashi, Sachiko Ito
  • Publication number: 20140087969
    Abstract: The invention relates to isolated nucleic acid molecules and to host cells comprising such nucleic acid molecules. Moreover, the invention relates to a polypeptide having PIM-3 activity and having a definite amino acid sequence, as well as to the use of PIM-3 as a screening agent for identifying anti-type 2 diabetes mellitus drugs and for preparing a medicament for the treatment of insulin resistance or type 2 diabetes mellitus.
    Type: Application
    Filed: November 7, 2013
    Publication date: March 27, 2014
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Marc KORN, Guenter MUELLER, Rudolf SCHNEIDER, Georg TSCHANK
  • Publication number: 20140087392
    Abstract: A glycosyl transferase from Chinese hamster and related methods are described.
    Type: Application
    Filed: November 6, 2013
    Publication date: March 27, 2014
    Applicant: Momenta Pharmaceuticals, Inc.
    Inventor: James W. Meador, III
  • Publication number: 20140087970
    Abstract: In some aspects, the invention provides compounds and methods of use for treating tumors. In some aspects, the methods comprise administering a serine biosynthesis pathway inhibitor to a subject, wherein the subject has a tumor that overexpresses PHGDH In some embodiments, the tumor is an ER negative breast cancer. In some aspects, the invention provides an in vivo RNAi-based negative selection screen of use to identify drug targets for treatment of tumors.
    Type: Application
    Filed: March 30, 2012
    Publication date: March 27, 2014
    Applicant: Whitehead Institute for Biomedical Research
    Inventors: Richard Possemato, David M. Sabatini
  • Publication number: 20140080142
    Abstract: Differentiated cholinergic cells having motor neuron-like morphology and increased sensitivity to botulinum neurotoxin are provided herein. Methods of using such differentiated cells for detecting neurotoxin are also provided.
    Type: Application
    Filed: February 28, 2013
    Publication date: March 20, 2014
    Applicant: WISCONSIN ALUMNI RESEARCH FOUNDATION
    Inventors: Eric Arthur Johnson, Regina Whitemarsh, Sabine Pellett
  • Publication number: 20140080838
    Abstract: The present disclosure identifies a novel subtype of follicular lymphoma (FL) characterized by dysregulation of the cyclin/CDK/RB proliferative pathway. This subtype of FL is associated with increased malignancy and mortality, relative to FL which is not associated with cell cycle dysregulation. Accordingly, this disclosure presents novel methods to subtype FL and stratify patient risk by detection of biomarkers associated with RB inactivation. This disclosure further presents novel therapies for the treatment of FL subtyped by inactivation of RB.
    Type: Application
    Filed: March 14, 2013
    Publication date: March 20, 2014
    Applicant: Memorial Sloan-Kettering Cancer Center
    Inventors: Hans Guido WENDEL, Elisa Oricchio
  • Publication number: 20140080733
    Abstract: Personalized medicine involves the use of a patient's molecular markers to guide treatment regimens for the patient. The scientific literature provides multiple examples of correlations between drug treatment efficacy and the presence or absence of molecular markers in a patient sample. Methods are provided herein that permit efficient dissemination of scientific findings regarding treatment efficacy and molecular markers found in patient tumors to health care providers.
    Type: Application
    Filed: September 13, 2013
    Publication date: March 20, 2014
    Applicant: Aueon, Inc.
    Inventors: Dietrich Stephan, Vern Norviel, Janet Warrington, Doug Dolginow
  • Publication number: 20140080737
    Abstract: The invention provides gene expression profiles (GEPs), protein expression profiles (PEPs) as well as gene/protein expression profiles (GPEPs) and methods for using them to identify metastatic breast cancer patients who are likely to respond to therapy with a VEGF inhibitor. The present invention allows a treatment provider to identify those patients who are most likely to respond to such treatment, and to initiate and/or adjust treatment options for such patients accordingly.
    Type: Application
    Filed: April 13, 2012
    Publication date: March 20, 2014
    Applicant: NUCLEA BIOTECHNOLOGIES, INC.
    Inventor: Patrick J. Muraca
  • Publication number: 20140079718
    Abstract: The present invention provides compositions and methods for detection, diagnosis, treatment and/or prevention of chronic pelvic pain syndrome. In particular, the present invention provides biomarkers of chronic pelvic pain syndrome (e.g., mast cell markers (e.g., tryptase)), and/or inhibition of mast cell function (e.g. inhibition of MCP-1 and/or MIP-1?) to treat or prevent chronic pelvic pain syndrome.
    Type: Application
    Filed: November 19, 2013
    Publication date: March 20, 2014
    Applicant: Northwestern University
    Inventors: Praveen Thumbikat, Anthony J. Schaeffer, Joseph Done, David J. Klumpp, Charles Rudick
  • Publication number: 20140080144
    Abstract: The present invention relates to a routine in vitro method for determining platelet-associated analytes, for example VWF, factor XIII, fibrinogen or D-dimer, in a sample of platelet-rich plasma.
    Type: Application
    Filed: September 18, 2013
    Publication date: March 20, 2014
    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS PRODUCTS GMBH
    Inventor: Juergen Patzke
  • Publication number: 20140080782
    Abstract: A method of diagnosing pancreatic cancer in a subject is provided. The method comprising determining a level and/or activity of at least one saliva secreted marker in a saliva sample of the subject wherein an alteration in said marker with respect to an unaffected saliva sample is indicative of the pancreatic cancer.
    Type: Application
    Filed: December 13, 2011
    Publication date: March 20, 2014
    Applicant: Hadasit Medical Research Services and Development Ltd.
    Inventors: Aaron Palmon, Omer Deutsch, Doron Aframian, Oren Lahav
  • Publication number: 20140080810
    Abstract: The invention is directed to Compounds of Formula I: (I) and pharmaceutically acceptable salts or solvates thereof, as well as methods of treating using the compounds, methods for screening for inhibitor compounds and methods for identifying treatment regimens.
    Type: Application
    Filed: November 15, 2011
    Publication date: March 20, 2014
    Applicant: Exelixis, Inc.
    Inventors: Kenneth D. Rice, David Markby
  • Publication number: 20140079717
    Abstract: Provided are methods for characterizing microvesicles or other membranous structures. The methods involve assaying samples for microvesicles or other membranous structures, and include in certain aspects determining the presence or absence of tissue transglutaminase (tTG) and/or cross-linked fibronection (FN). The microvesicles or other membranous structures can be separated from a sample using recombinant tTG or a derivative of it, or tTG or FN binding partners. Also provided are methods for inhibiting the transfer of cargo from microvesicles which contain tTG to one or more cells. This involves administering to the individual a tTG inhibitor, such as a cell-impermeable tTG inhibitor. Also provided are compositions which contain a population of microvesicles or other membranous structures, where the population is attached to tTG or a derivative thereof, or to tTG or an FN binding partner. Kits which contain reagents and other components for carrying out the method are also provided.
    Type: Application
    Filed: February 17, 2012
    Publication date: March 20, 2014
    Applicant: CORNELL UNIVERSITY
    Inventors: Rick Cerione, Marc Antonyak, Kristin Wilson Cerione, Bo Li
  • Publication number: 20140080872
    Abstract: Use of phospho-Akt as a biomarker for predicting the response, such as resistance, to a compound, wherein phospho-Akt is Akt that has been phosphorylated on one or more residues, with the proviso that for Akt1, Akt2, and Akt3 the designation phospho-Akt is used to indicate phosphorylation at a site other than T308, T309 or T305 respectively, wherein the compound is a compound of general formula (I) wherein R represents phenyl, thienyl or pyridinyl wherein phenyl is optionally substituted by one or two substituents independently selected from alkyl, halo-lower alkyl, hydroxy-lower alkyl, lower alkoxy-lower alkyl, acyloxy-lower alkyl, phenyl, hydroxy, lower alkoxy, hydroxy-lower alkoxy, lower alkoxy-lower alkoxy, phenyl-lower alkoxy, lower alkylcarbonyloxy, amino, monoalkylamino, dialkylamino, lower alkoxycarbonylamino, lower alkylcarbonylamino, substituted amino wherein the two substituents on nitrogen form together with the nitrogen heterocyclyl, lower alkylcarbonyl, carboxy, lower alkoxycarbonyl, cyano, halo
    Type: Application
    Filed: March 28, 2012
    Publication date: March 20, 2014
    Inventors: Heidi Alexandra Lane, Felix Bachmann
  • Publication number: 20140080143
    Abstract: Provided is a method for the simple and highly accurate assay of PSA by a one-step reaction that does not use carriers having different average grain sizes. Also provided is a reagent therefor. The PSA assay method comprises sensitizing insoluble carriers having the same average grain size within a range of greater than 0.20 ?m but 0.40 ?m or less using two types of anti-PSA monoclonal antibodies having different epitopes that are anti-PSA monoclonal antibodies that will react with both free PSA and PSA-ACT, which is a complex of free PSA and ?1-antichymotrypsin, and bringing the carriers into contact with a sample in the presence of an aggregation promoter.
    Type: Application
    Filed: March 28, 2012
    Publication date: March 20, 2014
    Applicant: SEKISUI MEDICAL CO., LTD.
    Inventors: Yuki Takahashi, Tomo Shimizu, Yasushi Nakamura, Shinya Nakayama, Shinichiro Kitahara
  • Patent number: 8673583
    Abstract: Described herein are monoclonal antibodies and methods useful for determining and quantitating the presence of AAD-1 (aryloxyalkanoate dioxygenase) enzyme. These monoclonal antibodies are surprisingly well suited for detecting AAD-1 transgenic event gene products in a variety of plants and plant tissues. The invention further provides quantitative and qualitative immunoassays using the immunoglobulins of the invention.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: March 18, 2014
    Assignee: Dow AgroSciences, LLC.
    Inventors: Shawna K. Embrey, Gaofeng Lin, Guomin Shan
  • Patent number: 8673302
    Abstract: The present invention relates to the field of prognosis and/or diagnosis of a proliferative disease in a patient. More particularly, the invention relates to antibodies capable of binding to the human cMet receptor, as well as the amino acid and nucleic acid sequences coding for these antibodies. The invention likewise comprises the use of said antibodies, and corresponding processes, for detecting and diagnosing pathological hyperproliterative oncogenic disorders associated with expression of cMet. In certain embodiments, the disorders are oncogenic disorders associated with increased expression of cMet polypeptide relative to normal or any other pathology connected with the overexpression of cMet. The invention finally comprises products and/or compositions or kits comprising at least such antibodies for the prognosis or diagnostic of certain cancers.
    Type: Grant
    Filed: August 23, 2010
    Date of Patent: March 18, 2014
    Assignee: Pierre Fabre Medicament
    Inventors: Liliane Goetsch, Alexandra Jouhanneaud
  • Publication number: 20140072982
    Abstract: Methods by which specific biomarkers in saliva are used for risk detection, early diagnosis, prognosis and monitoring of Alzheimer's and Parkinson's diseases.
    Type: Application
    Filed: November 15, 2013
    Publication date: March 13, 2014
    Inventors: Balwant Rai, Jasdeep Kaur
  • Publication number: 20140072959
    Abstract: The present invention relates to rapid test devices, kits and systems comprising the rapid test devices for assessing at least two analytes in a sample derived from a life or health insurance applicant, said at least two analytes being selected from the group consisting of a human immunodeficiency virus (HIV) antigen (e.g., a HIV polypeptide), a HIV polynucleotide, an anti-HIV antibody, a hepatitis C virus (HCV) antigen (e.g., a HCV polypeptide), a HCV polynucleotide, an anti-HCV antibody, a liver enzyme alanine transaminase (ALT), a liver enzyme aspartate transaminase (AST), nt-probnp (or NT-proBNP), probnp (or proBNP), cotinine, nicotine, cocaine, a metabolite of cocaine (e.g., benzoylecgonine), prostate-specific antigen (PSA), apolipoprotein A-1 (ApoA1), apolipoprotein B (ApoB), Hemoglobin A1c and high-sensitivity C-reactive protein (hsCRP).
    Type: Application
    Filed: March 14, 2013
    Publication date: March 13, 2014
    Applicant: FORCE DIAGNOSTICS, INC.
    Inventors: Tedd C. DETERMAN, Michael P. CURRAN, Brian MULCONREY, David H. OSTROW
  • Publication number: 20140072963
    Abstract: Disclosed is an electrochemiluminescence immunoassay method, using a full reaction of a Ru(bpy) marked protein-primary antibody, a biotinylated protein-secondary antibody to be tested, and a sample to be tested; addition of a Streptavidin-coated magnetic particle to form a complex comprising an antigen, an antibody, and a magnetic particle; adsorption to an electrode surface by the magnetic particle; addition of a dibutyl ethanolamine solution; testing by means of an electrochemical method. Also disclosed is a corresponding electrochemiluminescence immunoassay detection kit.
    Type: Application
    Filed: March 13, 2012
    Publication date: March 13, 2014
    Applicant: BEIJING UNIDIAG TECHNOLOGY INC
    Inventor: Jun Qin
  • Publication number: 20140066321
    Abstract: Provided are histidyl-tRNA synthetase variant polypeptides, X-ray crystallographic and NMR spectroscopy structures of HRS polypeptides, and related compositions and methods for therapy and drug discovery.
    Type: Application
    Filed: July 23, 2013
    Publication date: March 6, 2014
    Applicants: aTyr Pharma, Inc.
    Inventors: Zhiwen Xu, Zhiyi Wei, Xiang-Lei Yang, Mingjie Zhang, Paul Schimmel
  • Publication number: 20140066461
    Abstract: Genetic markers of schizophrenia (SCZ) are presented herein, as are methods for using same for assessing risk of developing SCZ and diagnosing SCZ. Methods for choosing a therapeutic regimen and predicting and/or determining efficacy of a therapeutic regimen based on these genetic markers are also encompassed herein.
    Type: Application
    Filed: September 3, 2013
    Publication date: March 6, 2014
    Inventor: Dolores Malaspina
  • Publication number: 20140066464
    Abstract: A method of determining the susceptibility of a cancer in a subject to treatment with an antimetabolite includes obtaining a sample of cancer cells from the subject, measuring the level of UDG expression in the cancer cells, and comparing the measured levels of UDG expression in the cancer cells to a control level.
    Type: Application
    Filed: May 22, 2013
    Publication date: March 6, 2014
    Applicant: Case Western Reserve University
    Inventor: Case Western Reserve University
  • Publication number: 20140065642
    Abstract: The present invention generally provides systems and methods for the detection, identification, or characterization of differences between properties or behavior of corresponding species in two or more mixtures comprised of molecules, including biomolecules and/or molecules able to interact with biomolecules, using techniques such as partitioning. The experimental conditions established as distinguishing between the mixtures of the molecules using the systems and methods of the invention can also be used, in some cases, for further fractionation and/or characterization of the biomolecules and/or other molecules, using techniques such as single-step or multiple-step extraction, and/or by liquid-liquid partition chromatography. The methods could also be used for discovering and identifying markers associated with specific diagnostics, and can be used for screening for such markers once discovered and identified during diagnostics screening.
    Type: Application
    Filed: October 9, 2013
    Publication date: March 6, 2014
    Applicant: Analiza, Inc.
    Inventors: Arnon Chait, Boris Y. Zaslavsky
  • Publication number: 20140065641
    Abstract: A system enabling the molecular biological visualization and quantitative detection of events in a stress-exposed living organism and a means enabling the management of stress are provided. An indicator agent for non-inflammatory stress responses mediated by superoxide, which comprises IL-18, a visualizing agent for non-inflammatory stress responses for detecting the aforementioned indicator agent, a method of measuring the degree of non-inflammatory stress, which comprises using the aforementioned visualizing agent, a method of preventing, ameliorating or predicting a change in immune status based on a non-inflammatory stress response, which comprises applying the aforementioned visualizing agent to an animal, and a therapeutic agent for a change in immune status based on a non-inflammatory stress response for reducing the amount or activity of the aforementioned indicator agent.
    Type: Application
    Filed: October 7, 2013
    Publication date: March 6, 2014
    Inventor: Atsuo SEKIYAMA
  • Publication number: 20140065610
    Abstract: An in vitro method of predicting whether a patient, having a neurodevelopmental, neurological or neuropsychiatric disorder, will derive a clinical benefit if treated with a glycine reuptake inhibitor (GRI), via determination of the protein concentration of one, two, three, four five or six members of the complement factor H family or a mixture or a combination thereof and comparison against a representative value, wherein a higher value of the protein concentration in the patient's sample against the representative value is indicative of a patient whom will derive clinical benefit from treatment with GRI.
    Type: Application
    Filed: August 21, 2012
    Publication date: March 6, 2014
    Inventors: Laurent Essioux, Carsten Horn, Johann Karl, Peter Kastner, Fabian Model, Giuseppe Palermo, Christina Rabe, Daniel Umbricht, Gabriel Vargas, Anne Vogt
  • Patent number: 8663941
    Abstract: The present disclosure relates to a method for diagnosing the ischemic state in a subject suffering from acute coronary syndrome who does not fulfilling the diagnostic criteria for a myocardial infarction. The present disclosure also relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome but does not fulfill the diagnostic criteria for a myocardial infarction. The methods of the present disclosure are based on the determination of fms-like tyrosine kinase-1 (sFLT-1) and, optionally, hepatocyte growth factor (HGF) in a sample of said subject. The present disclosure also relates to kits and/or devices for carrying out the methods disclosed herein.
    Type: Grant
    Filed: May 24, 2012
    Date of Patent: March 4, 2014
    Assignee: Roche Diagnostics Operations, Inc.
    Inventors: Georg Hess, Andrea Horsch, Dietmar Zdunek
  • Publication number: 20140056911
    Abstract: To gain a better understanding of breast tumor angiogenesis, breast endothelial cells (ECs) were isolated and evaluated for gene expression patterns. When transcripts from breast ECs derived from normal and malignant breast tissues were compared, genes that were specifically elevated in tumor-associated breast endothelium were revealed. These results confirm that neoplastic and normal endothelium in human breast are distinct at the molecular level, and have significant implications for the development of anti-angiogenic therapies in the future.
    Type: Application
    Filed: October 29, 2013
    Publication date: February 27, 2014
    Applicants: Genzyme Corporation, The Johns Hopkins University
    Inventors: Saraswati SUKUMAR, Stephen L. MADDEN
  • Publication number: 20140057251
    Abstract: Using the efficiency of next generation sequencing, a draft de novo reference sequence for the Cannabis (C.) Sativa and C. Indica genomes has been generated as well as four full length contiguous sequences with homology to THCA and CBDA synthases and 10 partially homologous contigs with truncated ORFs. In particular aspects the invention is directed to an (one or more) isolated sequence (e.g., nucleic acid sequence, DNA, RNA, genomic sequence, polypeptide) of a Cannabis genome and uses thereof.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 27, 2014
    Applicant: Medicinal Genomics Corporation
    Inventor: Kevin McKernan
  • Publication number: 20140057967
    Abstract: The present invention relates to a method of screening for modulator of chaperonin that is involved in protein aggregation inducing neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease, use of the chaperonin modulator screened by the method for prevention and treatment of neurodegenerative diseases. According to the present invention, novel negative chaperonin modulator is provided, and chaperonin modulator may be more rapidly and conveniently screened with the negative modulator as a target. Furthermore, by using the screened material, neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease may be effectively prevented or treated without concern for cell death due to autophagy, which is the existing method of removing protein aggregate.
    Type: Application
    Filed: August 20, 2012
    Publication date: February 27, 2014
    Applicant: Postech Academy-Industry Foundation
    Inventors: Kyong Tai Kim, Sangjune Kim
  • Publication number: 20140057285
    Abstract: In some aspects, the invention provides chimeric kinesin proteins. In other aspects the invention provides nucleic acids encoding chimeric kinesin proteins. Compositions and kits are provided that comprise chimeric kinesin proteins and nucleic acids encoding the same. Antibodies and antigen binding fragments that selectively bind kinesin proteins are also provided.
    Type: Application
    Filed: March 5, 2012
    Publication date: February 27, 2014
    Inventors: Matthew J. Lang, William Hesse, Wonmuk Hwang, Martin Karplus
  • Patent number: 8658388
    Abstract: The present invention provides antibody-based arrays for detecting the activation state and/or total amount of a plurality of signal transduction molecules in rare circulating cells and methods of use thereof for facilitating cancer prognosis and diagnosis and the design of personalized, targeted therapies.
    Type: Grant
    Filed: March 11, 2008
    Date of Patent: February 25, 2014
    Assignee: Nestec S.A.
    Inventors: Jeanne Harvey, Sharat Singh, Phillip Kim, Xinjun Liu, Robert Barham, Limin Liu
  • Patent number: 8658431
    Abstract: A method and kit for determining whether an animal is not pregnant, or is pregnant following a breeding. The level of expression of a pregnancy induced protein is determined in an animal for which pregnancy status information is desired and the level is compared to that of the level in animals that are not pregnant.
    Type: Grant
    Filed: September 13, 2006
    Date of Patent: February 25, 2014
    Assignee: Idaho Research Foundation
    Inventor: Troy L. Ott
  • Publication number: 20140051594
    Abstract: The present invention provides methods, systems, and code for accurately classifying whether a sample from an individual is associated with irritable bowel syndrome (IBS). In particular, the present invention is useful for classifying a sample from an individual as an IBS sample using a statistical algorithm and/or empirical data. The present invention is also useful for ruling out one or more diseases or disorders that present with IBS-like symptoms and ruling in IBS using a combination of statistical algorithms and/or empirical data. Thus, the present invention provides an accurate diagnostic prediction of IBS and prognostic information useful for guiding treatment decisions.
    Type: Application
    Filed: May 9, 2013
    Publication date: February 20, 2014
    Inventor: Augusto Lois
  • Publication number: 20140051094
    Abstract: The present invention relates to a method for determining the amount of a physiologically acceptable polymer molecule bound to a protein, an antibody or other composition being capable of specifically binding to a physiologically acceptable polymer molecule, and a kit containing said antibody or composition.
    Type: Application
    Filed: September 13, 2013
    Publication date: February 20, 2014
    Applicants: Baxter Healthcare SA, Baxter International Inc.
    Inventors: Peter Turecek, Juergen Siekmann, Alfred Weber, Herbert Gritsch, Katalin Varadi, Susanne Vejda
  • Publication number: 20140050662
    Abstract: The invention provides a family of agents that target the prostate specific antigen, which can be used as imaging agents or therapeutic agents. The agents can be used to image prostate cancer as well as other physiological processes in a subject.
    Type: Application
    Filed: March 15, 2013
    Publication date: February 20, 2014
    Inventor: Guojie Ho
  • Publication number: 20140050740
    Abstract: Provided are methods of treating tissue fibrosis comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a hyaluron synthase (HAS) or CD44. Further provided are methods of inhibiting myofibroblast invasion, or of reducing matrix deposition in the lung, the methods comprising administering to a subject in need of treatment an effective amount of an agent that inhibits a HAS or CD44. Further provided are methods of determining the progression of pulmonary fibrosis, the methods comprising determining the level of matrix metalloproteinase expression in a cell, and comparing the level of expression to that of a control cell, wherein an increased level of expression relative to the control cell indicates progression of the disease.
    Type: Application
    Filed: April 12, 2012
    Publication date: February 20, 2014
    Applicant: DUKE UNIVERSITY
    Inventors: Paul W. Noble, Dianhua Jiang
  • Publication number: 20140051093
    Abstract: The present invention relates to the field of recombinant toxin protein production in bacterial hosts. In particular, the present invention relates to production processes for obtaining high levels of a recombinant CRM197, Diphtheria Toxin, Pertussis Toxin, Tetanus Toxoid Fragment C, Cholera Toxin B, Cholera holotoxin, and Pseudomonas Exotoxin A, from a bacterial host.
    Type: Application
    Filed: July 26, 2013
    Publication date: February 20, 2014
    Applicant: Pfenex Inc.
    Inventors: Diane M. Retallack, Lawrence Chew
  • Publication number: 20140050722
    Abstract: A chimeric monoclonal antibody targeted to ricin is presented. The light chain and heavy chain constant regions are respectively made up of the light chain and heavy chain constant regions of human immunoglobulin, and the light chain and heavy chain variable regions respectively include the light chain and heavy chain variable regions of macaque immunoglobulin. The antibody does not substantially induce any immune response against chimeric antibodies.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 20, 2014
    Applicants: LFB BIOTECHNOLOGIES, ETAT FRANCAIS REPRESENTE PAR LE DELEGUE GENERAL POUR L'ARMEMENT
    Inventors: Philippe THULLIER, Alexandre FONTAYNE